AXID Drug Patent Profile
✉ Email this page to a colleague
When do Axid patents expire, and when can generic versions of Axid launch?
Axid is a drug marketed by Smithkline Beecham, Braintree, and Haleon Us Holdings. and is included in three NDAs.
The generic ingredient in AXID is nizatidine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nizatidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Axid
A generic version of AXID was approved as nizatidine by EPIC PHARMA LLC on July 5th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AXID?
- What are the global sales for AXID?
- What is Average Wholesale Price for AXID?
Summary for AXID
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Patent Applications: | 5,012 |
| DailyMed Link: | AXID at DailyMed |
Paragraph IV (Patent) Challenges for AXID
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AXID | Oral Solution | nizatidine | 15 mg/mL | 021494 | 1 | 2008-05-14 |
US Patents and Regulatory Information for AXID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithkline Beecham | AXID | nizatidine | CAPSULE;ORAL | 019508-001 | Apr 12, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Haleon Us Holdings | AXID AR | nizatidine | TABLET;ORAL | 020555-001 | May 9, 1996 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Smithkline Beecham | AXID | nizatidine | CAPSULE;ORAL | 019508-002 | Apr 12, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AXID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | AXID | nizatidine | CAPSULE;ORAL | 019508-001 | Apr 12, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Smithkline Beecham | AXID | nizatidine | CAPSULE;ORAL | 019508-002 | Apr 12, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Smithkline Beecham | AXID | nizatidine | CAPSULE;ORAL | 019508-002 | Apr 12, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AXID
See the table below for patents covering AXID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2003247769 | TASTE-MASKED LIQUID PHARMACEUTICAL COMPOSITION COMPRISING A COMPLEX OF A HISTAMINE h2-RECEPTOR ANTAGONIST AND ALGINATE | ⤷ Sign Up |
| Germany | 3171819 | ⤷ Sign Up | |
| Netherlands | 930107 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
